Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has appointed Ian Read, the current head of Global Biopharmaceutical Operations, as president, CEO and director, replacing Jeffrey Kindler, who has retired from the company.
Subscribe to our email newsletter
Since 2006, Read has led Pfizer‘s Worldwide Biopharmaceutical Businesses which now comprises five global business units – Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets – and accounts for approximately 85% of Pfizer’s annual revenues.
His leadership team consisted of senior executives directing Pfizer development and commercial operations in 180 nations.
Read joined Pfizer in 1978 and later assumed positions of increasing responsibility in Latin America.
In 1996, he was appointed president of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He was named corporate VP in 2001, and assumed responsibility for Europe in addition to Canada. He later added the Africa/Middle East and Latin American regions to his leadership responsibility.
Kindler said the combination of meeting the requirements of many stakeholders around the world and the 24/7 nature of responsibilities, has made this period extremely demanding on him personally.
Read said they have a broad portfolio that spans the entire spectrum of human and animal health, from vaccines to biologics to primary care, specialty care, oncology, consumer products, nutritionals and beyond.
"We have all the elements for success – financial strength, global reach, a disciplined focus on the therapeutic areas with the strongest growth potential and a talented and dedicated workforce," Read said.